Neuromuscular Responses to Acute Beetroot Ingestion in Women Older Adults

NCT05337527 | Completed

• 1 other identifier: uFrancisco_Vitoria_
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

Beetroot juice supplementation has shown the capacity for provoking different physiological effects (e.g. vasodilation and muscle contraction increments). However, the effects of beetroot juice ingestion on neuromuscular performance in women older adults are barely studied. In this randomized placebo-controlled study, we investigated the effects of beetroot acute supplementation in improving neuromuscular performance in women older adults

Conditions

Dietary Supplement; Placebo

Keywords

dietary supplements; nitrate; neuromuscular function

Outcome Measures

Primary Outcomes (5)

• Changes in maximal isometric handgrip strength (N)

  Using a dynamometer and measuring dominant/ non-dominant side

  1-week

• Changes in 6-m gait speed test

  Using a photocell timing gates (seconds)

  1-week

• Changes in Time Up and Go test

  Using a photocell timing gates (seconds)

  1-week

• Changes in Sit and Stand Test

  Using Power Frail APP

  1-week

• 6-Minute Walk Test

  1-week

Secondary Outcomes (2)

• Rate of perception effort (RPE)

  1-week

• Side effects questionnarie

  1-week

Study Arms (2)

Beetroot supplementation

EXPERIMENTAL

One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.

Dietary Supplement: beetroot juice

Placebo supplementation

PLACEBO COMPARATOR

One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.

Dietary Supplement: beetroot juice

Interventions

beetroot juice DIETARY_SUPPLEMENT

Acute effects of beetroot juice or placebo juice ingestion

Beetroot supplementation; Placebo supplementation

Eligibility Criteria

• Age: 65 Years - 80 Years
• Gender Eligibility Details: Only women older adults were selected for this study.
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• Women \>65 or \<85 years of age.
• In good health, as determined by the investigator's review of history.

You may not qualify if:

• Men and women \<65 or \>85 years of age Unable to provide informed consent Current smokers Significant orthopedic limitations or other contraindications to strenuous exercise Those taking proton pump inhibitors, antacids, xanthine oxidase inhibitors, or on hormone replacement therapy Those taking anti-coagulants or on anti-platelet therapy History of neuromuscular disease (e.g., cervical spondylotic radiculomyelpathy, lumbar spondylosis, amyotrophic lateral sclerosis, Guillain-Barré syndrome, and acquired demyelinating polyneuropathies) Cardiovascular disease (e.g., \> stage I hypertension, heart failure, myocardial infarction/ischemia significant myocardial or pericardial diseases (e.g. amyloidosis, constriction), Moderate or severe valvular disease, renal disease, liver disease, or anemia

Sponsors & Collaborators

• Universidad Francisco de Vitoria: lead

Study Sites (1)

Universidad Francisco de Vitoria

Pozuelo de Alarcón, Madrid, 28223, Spain

Location

Study Officials

• Alvaro López Samanes, PhD

  Universidad Francisco de Vitoria

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD

Study Record Dates

• First Submitted: April 13, 2022
• First Posted: April 20, 2022
• Study Start: March 1, 2022
• Primary Completion: March 18, 2022
• Study Completion: April 10, 2022
• Last Updated: May 9, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)